Minerva Neurosciences (NASDAQ:NERV – Get Free Report) posted its earnings results on Friday. The biopharmaceutical company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($1.46), Zacks reports.
Minerva Neurosciences Stock Performance
NASDAQ NERV traded up $0.12 during trading hours on Friday, reaching $2.42. 238,027 shares of the company were exchanged, compared to its average volume of 193,865. The business’s 50 day simple moving average is $3.22 and its 200-day simple moving average is $4.83. Minerva Neurosciences has a 1 year low of $1.96 and a 1 year high of $8.80.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Minerva Neurosciences in a report on Monday, September 21st. Wall Street Zen cut Minerva Neurosciences from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. Zacks Research raised shares of Minerva Neurosciences from a “strong sell” rating to a “hold” rating in a report on Friday, October 9th. Finally, Jefferies Financial Group upgraded shares of Minerva Neurosciences from a “hold” rating to a “mixed” rating and upped their target price for the stock from $7.50 to $10.00 in a research note on Friday, August 14th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Minerva Neurosciences has an average rating of “Hold” and a consensus price target of $10.33.
Read Our Latest Report on NERV
About Minerva Neurosciences
Minerva Neurosciences, Inc is a biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s research has centered on conditions with significant unmet medical needs, including schizophrenia, depression and other psychiatric or neurological diseases.
Minerva’s lead product candidate has been roluperidone, an investigational therapy designed to address the negative symptoms of schizophrenia, such as social withdrawal, reduced motivation and diminished emotional expression.
Read More
- Five stocks we like better than Minerva Neurosciences
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
